earnings
confidence high
sentiment positive
materiality 0.80
Amneal reports Q4 2025 net revenue $814M (+11% YoY); FY25 rev $3.02B; 2026 guidance $3.05-$3.15B
Amneal Pharmaceuticals, Inc.
2025-FY EPS reported
$0.22
revenue$3,018,760,000
- Q4 2025 net revenue $814M (+11% YoY); GAAP net income $35M; diluted EPS $0.11.
- Full year 2025 net revenue $3.02B (+8% YoY); GAAP net income $72M; diluted EPS $0.22.
- Adjusted EBITDA FY25 $688M (+10% YoY); Q4 adj EBITDA $175M.
- FY25 adj diluted EPS $0.83 vs $0.58 prior year; Q4 adj EPS $0.21 vs $0.12.
- 2026 guidance: net revenue $3.05-$3.15B, adj EBITDA $720-$760M, adj EPS $0.93-$1.03.